Urodynamic findings and long-term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction.
We studied urodynamically 46 patients between 20 and 74 years old with multiple sclerosis and uncomfortable bladder symptoms. The response to treatment was recorded during a followup of 1 to 10 years (mean 3 1/2 years). Lack of response to appropriate therapy predicated on urodynamic testing appeared to be related to progression of multiple sclerosis.
D000328:Adult; D000368:Aged; D018723:Bethanechol; D001626:Bethanechol Compounds / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications* / Q000503:physiopathology; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000503:physiopathology; D010276:Parasympatholytics / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D012021:Reflex, Abnormal / Q000209:etiology / Q000503:physiopathology; D013997:Time Factors; D001743:Urinary Bladder / Q000503:physiopathology*; D001750:Urinary Bladder, Neurogenic / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D014546:Urinary Catheterization; D014563:Urodynamics
D001626:Bethanechol Compounds; D008333:Mandelic Acids; D010276:Parasympatholytics; D018723:Bethanechol; D010643:Phenoxybenzamine; C005419:oxybutynin; D007099:Imipramine